The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions
Single Dose Crossover Comparative Bioavailability Study of Candesartan Cilexetil 32 mg Tablets in Healthy Adult Subjects Under Fasting Conditions
Sponsor: Altasciences Company Inc.
Listed as NCT04012307, this PHASE1 trial focuses on Bioequivalence and remains completed. Sponsored by Altasciences Company Inc., it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Oct 2023 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Dec 2019 — Jun 2020 [monthly]
Completed PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Completed PHASE1
Status: Not Yet Recruiting → Completed
-
Aug 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Altasciences Company Inc.
- Pharmtechnology LLC
For direct contact, visit the study record on ClinicalTrials.gov .